世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

神経痛治療 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030


Nerve Pain Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

神経痛治療の世界市場規模は2023年に100万米ドルと推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。 世界の医薬品市場は2022年に1,475億米ドルで、今後6... もっと見る

　

　

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ 		2024年3月22日 US$3,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。
日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


　

サマリー

神経痛治療の世界市場規模は2023年に100万米ドルと推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。
世界の医薬品市場は2022年に1,475億米ドルで、今後6年間のCAGRは5％で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要としている患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。
レポートの範囲
本レポートは、神経痛治療の世界市場を包括的に紹介することを目的としており、神経痛治療の地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングに焦点を当てています。
神経痛治療の市場規模、推計、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供します。定量分析および定性分析により、読者が事業/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、神経痛治療に関する情報に基づいたビジネス上の意思決定を行うことを支援します。
市場区分
企業別
ファイザー
ジョンソン・エンド・ジョンソンサービス社
ブリストル・マイヤーズ スクイブ社
サノフィ
グラクソスミスクライン
イーライリリー・アンド・カンパニー
テバ・ファーマシューティカル・インダストリーズ社
バクスター・インターナショナル
タイプ別セグメント
三環系抗うつ薬
オピオイド
抗けいれん薬
その他
用途別セグメント
病院
小売薬局
その他
地域別
北米
米国
カナダ
欧州
ドイツ
フランス
英国
イタリア
ロシア
アジア太平洋
中国
日本
韓国
中国 台湾
東南アジア
インド
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
各章の概要
第1章： レポートのスコープ、世界の総市場規模を紹介。また、市場力学、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。
第2章 神経痛治療メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。
第3章：タイプ別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのを助ける。
第4章：用途別の様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性をカバーし、読者が異なる下流市場のブルーオーシャン市場を見つけるのを助ける。
第5章：地域レベルでの神経痛治療の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見込み、市場スペース、市場規模を紹介しています。
第6章 神経痛治療の国別収益。各国・地域のタイプ別、用途別のシグメイトデータを提供しています。
第7章：主要企業のプロファイルを提供し、製品収益、売上総利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介します。
第8章：産業の上流と下流を含む産業チェーンの分析。
第9章：結論


ページTOPに戻る


目次

1 Market Overview
1.1 Nerve Pain Treatment Product Introduction
1.2 Global Nerve Pain Treatment Market Size Forecast
1.3 Nerve Pain Treatment Market Trends & Drivers
1.3.1 Nerve Pain Treatment Industry Trends
1.3.2 Nerve Pain Treatment Market Drivers & Opportunity
1.3.3 Nerve Pain Treatment Market Challenges
1.3.4 Nerve Pain Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Nerve Pain Treatment Players Revenue Ranking (2023)
2.2 Global Nerve Pain Treatment Revenue by Company (2019-2024)
2.3 Key Companies Nerve Pain Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Nerve Pain Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Nerve Pain Treatment
2.6 Nerve Pain Treatment Market Competitive Analysis
2.6.1 Nerve Pain Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Nerve Pain Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nerve Pain Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tricyclic Antidepressants
3.1.2 Opioids
3.1.3 Anticonvulsants
3.1.4 Others
3.2 Global Nerve Pain Treatment Sales Value by Type
3.2.1 Global Nerve Pain Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Nerve Pain Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Nerve Pain Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.1.3 Others
4.2 Global Nerve Pain Treatment Sales Value by Application
4.2.1 Global Nerve Pain Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Nerve Pain Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Nerve Pain Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Nerve Pain Treatment Sales Value by Region
5.1.1 Global Nerve Pain Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Nerve Pain Treatment Sales Value by Region (2019-2024)
5.1.3 Global Nerve Pain Treatment Sales Value by Region (2025-2030)
5.1.4 Global Nerve Pain Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Nerve Pain Treatment Sales Value, 2019-2030
5.2.2 North America Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Nerve Pain Treatment Sales Value, 2019-2030
5.3.2 Europe Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Nerve Pain Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Nerve Pain Treatment Sales Value, 2019-2030
5.5.2 South America Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Nerve Pain Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Nerve Pain Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Nerve Pain Treatment Sales Value
6.3 United States
6.3.1 United States Nerve Pain Treatment Sales Value, 2019-2030
6.3.2 United States Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nerve Pain Treatment Sales Value, 2019-2030
6.4.2 Europe Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Nerve Pain Treatment Sales Value, 2019-2030
6.5.2 China Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Nerve Pain Treatment Sales Value, 2019-2030
6.6.2 Japan Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Nerve Pain Treatment Sales Value, 2019-2030
6.7.2 South Korea Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Nerve Pain Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Nerve Pain Treatment Sales Value, 2019-2030
6.9.2 India Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Profile
7.1.2 Pfizer Inc. Main Business
7.1.3 Pfizer Inc. Nerve Pain Treatment Products, Services and Solutions
7.1.4 Pfizer Inc. Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Inc. Recent Developments
7.2 Johnson & Johnson Services, Inc
7.2.1 Johnson & Johnson Services, Inc Profile
7.2.2 Johnson & Johnson Services, Inc Main Business
7.2.3 Johnson & Johnson Services, Inc Nerve Pain Treatment Products, Services and Solutions
7.2.4 Johnson & Johnson Services, Inc Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Services, Inc Recent Developments
7.3 Bristol-Myers Squibb Company
7.3.1 Bristol-Myers Squibb Company Profile
7.3.2 Bristol-Myers Squibb Company Main Business
7.3.3 Bristol-Myers Squibb Company Nerve Pain Treatment Products, Services and Solutions
7.3.4 Bristol-Myers Squibb Company Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi S.A Recent Developments
7.4 Sanofi S.A
7.4.1 Sanofi S.A Profile
7.4.2 Sanofi S.A Main Business
7.4.3 Sanofi S.A Nerve Pain Treatment Products, Services and Solutions
7.4.4 Sanofi S.A Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi S.A Recent Developments
7.5 Glaxosmithkline plc
7.5.1 Glaxosmithkline plc Profile
7.5.2 Glaxosmithkline plc Main Business
7.5.3 Glaxosmithkline plc Nerve Pain Treatment Products, Services and Solutions
7.5.4 Glaxosmithkline plc Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Glaxosmithkline plc Recent Developments
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Profile
7.6.2 Eli Lilly and Company Main Business
7.6.3 Eli Lilly and Company Nerve Pain Treatment Products, Services and Solutions
7.6.4 Eli Lilly and Company Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Eli Lilly and Company Recent Developments
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Profile
7.7.2 Teva Pharmaceutical Industries Ltd Main Business
7.7.3 Teva Pharmaceutical Industries Ltd Nerve Pain Treatment Products, Services and Solutions
7.7.4 Teva Pharmaceutical Industries Ltd Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Teva Pharmaceutical Industries Ltd Recent Developments
7.8 Baxter International Inc.
7.8.1 Baxter International Inc. Profile
7.8.2 Baxter International Inc. Main Business
7.8.3 Baxter International Inc. Nerve Pain Treatment Products, Services and Solutions
7.8.4 Baxter International Inc. Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Baxter International Inc. Recent Developments
8 Industry Chain Analysis
8.1 Nerve Pain Treatment Industrial Chain
8.2 Nerve Pain Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Nerve Pain Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Nerve Pain Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

　

ページTOPに戻る


　

Summary

The global market for Nerve Pain Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nerve Pain Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Nerve Pain Treatment by region & country, by Type, and by Application.
The Nerve Pain Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nerve Pain Treatment.
Market Segmentation
By Company
Pfizer Inc.
Johnson & Johnson Services, Inc
Bristol-Myers Squibb Company
Sanofi S.A
Glaxosmithkline plc
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Baxter International Inc.
Segment by Type:
Tricyclic Antidepressants
Opioids
Anticonvulsants
Others
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nerve Pain Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Nerve Pain Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Nerve Pain Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.



ページTOPに戻る


Table of Contents

1 Market Overview
1.1 Nerve Pain Treatment Product Introduction
1.2 Global Nerve Pain Treatment Market Size Forecast
1.3 Nerve Pain Treatment Market Trends & Drivers
1.3.1 Nerve Pain Treatment Industry Trends
1.3.2 Nerve Pain Treatment Market Drivers & Opportunity
1.3.3 Nerve Pain Treatment Market Challenges
1.3.4 Nerve Pain Treatment Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Nerve Pain Treatment Players Revenue Ranking (2023)
2.2 Global Nerve Pain Treatment Revenue by Company (2019-2024)
2.3 Key Companies Nerve Pain Treatment Manufacturing Base Distribution and Headquarters
2.4 Key Companies Nerve Pain Treatment Product Offered
2.5 Key Companies Time to Begin Mass Production of Nerve Pain Treatment
2.6 Nerve Pain Treatment Market Competitive Analysis
2.6.1 Nerve Pain Treatment Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Nerve Pain Treatment Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nerve Pain Treatment as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tricyclic Antidepressants
3.1.2 Opioids
3.1.3 Anticonvulsants
3.1.4 Others
3.2 Global Nerve Pain Treatment Sales Value by Type
3.2.1 Global Nerve Pain Treatment Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Nerve Pain Treatment Sales Value, by Type (2019-2030)
3.2.3 Global Nerve Pain Treatment Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Retail Pharmacy
4.1.3 Others
4.2 Global Nerve Pain Treatment Sales Value by Application
4.2.1 Global Nerve Pain Treatment Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Nerve Pain Treatment Sales Value, by Application (2019-2030)
4.2.3 Global Nerve Pain Treatment Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Nerve Pain Treatment Sales Value by Region
5.1.1 Global Nerve Pain Treatment Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Nerve Pain Treatment Sales Value by Region (2019-2024)
5.1.3 Global Nerve Pain Treatment Sales Value by Region (2025-2030)
5.1.4 Global Nerve Pain Treatment Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Nerve Pain Treatment Sales Value, 2019-2030
5.2.2 North America Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Nerve Pain Treatment Sales Value, 2019-2030
5.3.2 Europe Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Nerve Pain Treatment Sales Value, 2019-2030
5.4.2 Asia Pacific Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Nerve Pain Treatment Sales Value, 2019-2030
5.5.2 South America Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Nerve Pain Treatment Sales Value, 2019-2030
5.6.2 Middle East & Africa Nerve Pain Treatment Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Nerve Pain Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Nerve Pain Treatment Sales Value
6.3 United States
6.3.1 United States Nerve Pain Treatment Sales Value, 2019-2030
6.3.2 United States Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nerve Pain Treatment Sales Value, 2019-2030
6.4.2 Europe Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Nerve Pain Treatment Sales Value, 2019-2030
6.5.2 China Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.5.3 China Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Nerve Pain Treatment Sales Value, 2019-2030
6.6.2 Japan Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Nerve Pain Treatment Sales Value, 2019-2030
6.7.2 South Korea Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Nerve Pain Treatment Sales Value, 2019-2030
6.8.2 Southeast Asia Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Nerve Pain Treatment Sales Value, 2019-2030
6.9.2 India Nerve Pain Treatment Sales Value by Type (%), 2023 VS 2030
6.9.3 India Nerve Pain Treatment Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer Inc.
7.1.1 Pfizer Inc. Profile
7.1.2 Pfizer Inc. Main Business
7.1.3 Pfizer Inc. Nerve Pain Treatment Products, Services and Solutions
7.1.4 Pfizer Inc. Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.1.5 Pfizer Inc. Recent Developments
7.2 Johnson & Johnson Services, Inc
7.2.1 Johnson & Johnson Services, Inc Profile
7.2.2 Johnson & Johnson Services, Inc Main Business
7.2.3 Johnson & Johnson Services, Inc Nerve Pain Treatment Products, Services and Solutions
7.2.4 Johnson & Johnson Services, Inc Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.2.5 Johnson & Johnson Services, Inc Recent Developments
7.3 Bristol-Myers Squibb Company
7.3.1 Bristol-Myers Squibb Company Profile
7.3.2 Bristol-Myers Squibb Company Main Business
7.3.3 Bristol-Myers Squibb Company Nerve Pain Treatment Products, Services and Solutions
7.3.4 Bristol-Myers Squibb Company Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.3.5 Sanofi S.A Recent Developments
7.4 Sanofi S.A
7.4.1 Sanofi S.A Profile
7.4.2 Sanofi S.A Main Business
7.4.3 Sanofi S.A Nerve Pain Treatment Products, Services and Solutions
7.4.4 Sanofi S.A Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.4.5 Sanofi S.A Recent Developments
7.5 Glaxosmithkline plc
7.5.1 Glaxosmithkline plc Profile
7.5.2 Glaxosmithkline plc Main Business
7.5.3 Glaxosmithkline plc Nerve Pain Treatment Products, Services and Solutions
7.5.4 Glaxosmithkline plc Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.5.5 Glaxosmithkline plc Recent Developments
7.6 Eli Lilly and Company
7.6.1 Eli Lilly and Company Profile
7.6.2 Eli Lilly and Company Main Business
7.6.3 Eli Lilly and Company Nerve Pain Treatment Products, Services and Solutions
7.6.4 Eli Lilly and Company Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.6.5 Eli Lilly and Company Recent Developments
7.7 Teva Pharmaceutical Industries Ltd
7.7.1 Teva Pharmaceutical Industries Ltd Profile
7.7.2 Teva Pharmaceutical Industries Ltd Main Business
7.7.3 Teva Pharmaceutical Industries Ltd Nerve Pain Treatment Products, Services and Solutions
7.7.4 Teva Pharmaceutical Industries Ltd Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.7.5 Teva Pharmaceutical Industries Ltd Recent Developments
7.8 Baxter International Inc.
7.8.1 Baxter International Inc. Profile
7.8.2 Baxter International Inc. Main Business
7.8.3 Baxter International Inc. Nerve Pain Treatment Products, Services and Solutions
7.8.4 Baxter International Inc. Nerve Pain Treatment Revenue (US$ Million) & (2019-2024)
7.8.5 Baxter International Inc. Recent Developments
8 Industry Chain Analysis
8.1 Nerve Pain Treatment Industrial Chain
8.2 Nerve Pain Treatment Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Nerve Pain Treatment Sales Model
8.5.2 Sales Channel
8.5.3 Nerve Pain Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（医療/ヘルスケア）の最新刊レポート

QYResearch社の医薬・ヘルスケア分野での最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/12/23　10:26

157.72 円

164.94 円

201.11 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.